Xbrane Biopharma AB (publ) ("The Company") has, according to previously published information, converted 10% of the outstanding convertible into shares in conjunction with the achievement of the first milestone related to the development of Spherotide.
Hence, the total number of shares and votes in The Company increased by 132 232 during September 2016. After the conversion, on October 31, 2016, the total number of shares and votes in The Company amounts to 4 755 546.
Xbrane is a commercial phase Swedish biopharmaceutical company specialized in High Demand Biosimilars and long acting injectables. Xbrane has world leading expertise in developing generics for long acting injectable drugs and proprietary high-yield protein expression technology for the development of biosimilars. Xbranes's headquarter is located in Stockholm and the company's in-house research and development facilities are in Sweden and Italy. Xbrane is listed at Nasdaq First North since February 3rd under the name XBRANE and Avanza Bank AB is Xbranes certified advisor. For more information see www.xbrane.com .
For further information, please contact:
Chief Executive Officer
M: +46 (0) 763-093 777
This information is information that Xbrane Biopharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8:00 October 31 2016.